Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01204255 · ClinicalTrials.gov registry record · NA
Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol Gel in Healthy Volunteers
A NA study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT01204255: Completed NA study, sponsored by Virginia Commonwealth University.
NCT01204255 is a NA study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 11 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01204255, a NA study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
RATIONALE: Lorazepam, diphenhydramine hydrochloride, and haloperidol gel, when absorbed into the skin, may be an effective treatment for nausea and vomiting.PURPOSE: This clinical trial studies lorazepam, diphenhydramine hydrochloride, and haloperidol gel in healthy volunteers.
Primary Outcome
Level of lorazepam absorption measured by the serum concentration of the drug
Interventions
- OTHER laboratory biomarker analysis
- OTHER questionnaire administration
- DRUG lorazepam
- DRUG haloperidol
- DRUG diphenhydramine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2010-11-15 |
| Est. Completion | 2011-05-17 |
| Phase | NA |
What the finished NCT01204255 record still lists
NCT01204255 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01204255 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01204255 about?
NCT01204255 is a clinical study titled "Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol Gel in Healthy Volunteers". RATIONALE: Lorazepam, diphenhydramine hydrochloride, and haloperidol gel, when absorbed into the skin, may be an effective treatment for nausea and vomiting.PURPOSE: This clinical trial studies lorazepam, diphenhydramine hydrochloride, and haloperidol gel in healthy volunteers.
What is the current status of trial NCT01204255?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2010-11-15. Estimated completion is 2011-05-17.
What interventions are being tested in trial NCT01204255?
The interventions under investigation include: laboratory biomarker analysis (OTHER), questionnaire administration (OTHER), lorazepam (DRUG), haloperidol (DRUG), diphenhydramine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01204255?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01204255's enrollment target sits among peer trials
11 1927th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI